证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-121 江苏吴中医药发展股份有限公司关于公司股票 可能存在因股价低于 1 元而终止上市的风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 一、公司股票可能被终止上市的原因 根据《股票上市规则》第 9.2.1 条第一款的规定：在上交所仅发行 A 股股票 的上市公司，如果连续 20 个交易日的每日股票收盘价均低于 1 元，公司股票可 能被上交所终止上市交易。公司股票 2025 年 10 月 14 日收盘价为 0.99 元/股， 低于人民币 1 元。如果出现"连续 20 个交易日的每日股票收盘价均低于人民币 1 元"的情形，公司股票可能被上交所终止上市交易。 江苏吴中医药发展股份有限公司(以下简称"公司")股票 2025 年 10 月 14 日收盘价为 0.99 元/股，低于人民币 1 元。根据《上海证券交易所股 票上市规则》（以下简称"《股票上市规则》"）第 9.2.1 条第一款第 一项规定，在上海证券交易所（以下简称"上交所"）仅发行 ...

Core Points - The company has provided a guarantee of 28.5 million RMB for its wholly-owned subsidiary, Jiangsu Wuzhong Medicine Group Co., Ltd. [2][3] - The total amount of guarantees provided by the company to the subsidiary amounts to 801.54 million RMB [2] - The company has a maximum guarantee limit of 1.84 billion RMB for the year 2025 [4] Guarantee Overview - The guarantee is for a bank loan agreement between Jiangsu Wuzhong Medicine Group and Jiangsu Bank, with a maximum guarantee amount of 28.5 million RMB [3] - The company has not provided any counter-guarantee for this loan [3] - The company has a total of 56.87 million RMB in overdue guarantees [3] Subsidiary Information - Jiangsu Wuzhong Medicine Group was established on September 29, 2005, with a registered capital of 740 million RMB [5] - The subsidiary's total assets as of the end of 2024 were 2.63 billion RMB, with total liabilities of 1.43 billion RMB, resulting in a debt-to-asset ratio of 54.27% [6] - For the first half of 2025, the subsidiary reported total assets of 2.11 billion RMB and a net loss of 30.07 million RMB [6] Guarantee Agreement Details - The guarantee covers the principal amount of 28.5 million RMB along with all related interest and fees [6][7] - The guarantee period extends until three years after the debt fulfillment period [7] - The company is responsible for any excess amounts due to currency fluctuations beyond the maximum guarantee amount [8] Board of Directors' Opinion - The board supports the guarantee to facilitate the subsidiary's normal banking operations and meet financing requirements [9] Total Guarantee Amount - As of the announcement date, the total guarantees provided by the company and its subsidiaries amount to 1.34 billion RMB, which is 73.70% of the company's latest audited net assets [10]

每经头条（nbdtoutiao）——AI技术滥用调查：明星可被"一键换装"，"擦边"内容成流量密码，技术防 线为何形同虚设？ （记者 曾健辉） 每经AI快讯，*ST苏吴（SH 600200，收盘价：1元）10月13日晚间发布公告称，江苏吴中医药发展股份 有限公司董事会于近日收到李锐先生的书面辞职报告，因个人原因，李锐先生申请辞去公司证券事务代 表、董事会办公室主任职务，辞职后将不在公司担任任何职务。 2024年1至12月份，*ST苏吴的营业收入构成为：药品行业占比76.9%，医美生科行业占比20.62%，贸易 行业占比1.32%，其他业务占比1.16%。 截至发稿，*ST苏吴市值为7亿元。 ...

证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-120 江苏吴中医药发展股份有限公司 关于为所属全资子公司提供担保进展的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 重要内容提示: 被担保人名称：江苏吴中医药集团有限公司(以下简称"吴中医药") 一、担保情况概述 （一）本次担保的基本情况 近日，公司与江苏银行股份有限公司苏州分行签署《最高额连带责任保证书》， 约定公司为吴中医药与江苏银行股份有限公司苏州分行签订的《流动资金借款合 同》提供最高额连带责任保证担保，最高担保额为人民币 2,850 万元。 （二）本次担保履行的内部决策程序 2025 年 4 月 29 日及 5 月 21 日，公司分别召开了第十一届董事会第四次会 议及 2024 年年度股东大会，审议通过了《江苏吴中医药发展股份有限公司关于 2025 年度为所属全资子公司提供担保的议案》。同意 2025 年度公司为所属全资 子公司提供担保的最高限额为 184,000 万元。本次担保事项在上述授权范围内， 无需另行召开董事会及股东大会。 本次担保金额及已实际为其提供 ...

2025 年 10 月 13 日，公司召开第十一届董事会 2025 年第三次临时会议（通 讯表决），审议通过了《关于聘任证券事务代表的议案》，经公司董事长提名，聘 任岳文哲先生（简历附后）为公司证券事务代表，协助公司董事会秘书履行职责， 任期自董事会审议通过之日起至本届董事会任期届满为止。 特此公告。 江苏吴中医药发展股份有限公司 董事会 2025 年 10 月 14 日 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-119 江苏吴中医药发展股份有限公司 关于变更证券事务代表的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）董事会于近日收到李 锐先生的书面辞职报告，因个人原因，李锐先生申请辞去公司证券事务代表、董 事会办公室主任职务，辞职后将不在公司担任任何职务。上述辞职报告自送达公 司董事会之日起生效。公司及董事会对其任职期间为公司发展所作出的贡献表示 衷心感谢！ 附件：岳文哲先生简历 岳文哲，男，1987 年出生，中国国籍，无境外永久居留权，硕 ...

New Stock Offerings - The tender offer for Shangwei New Materials (688585) is open from September 29, 2025, to October 28, 2025[1] - Zitian Tui (300280) is in the delisting adjustment period with only 2 trading days remaining until the last trading day[1] Market Alerts - Kesi Technology (688788) and Pinming Technology (688109) have recent announcements but no specific details provided[1] - Magu Technology (688448) is experiencing severe abnormal fluctuations[1] Trading Updates - Multiple companies including Dongjing (002199) and Guosheng Jinkong (002670) have announcements dated October 9, 2025, indicating ongoing trading activities[1] - Companies like Hunan Yuneng (301358) and Wanrun New Energy (688275) have announcements from October 1, 2025, indicating recent trading updates[1] Financial Disclosures - Several companies have disclosed their financial information, with specific announcements linked to their respective stock codes[1] - The report includes links to detailed announcements for various companies, providing transparency in their financial activities[1]

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-118 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第十三次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先 告知书》（处罚字〔2025〕58 号）。认定公司虚增营业收入、营业成本 和利润，2020 年至 2023 年年度报告存在虚假记载，触及重大违法强制 退市情形。公司股票已于 2025 年 7 月 14 日起被叠加实施重大违法类强 制退市风险警示。 如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司 股票将被终止上市。根据《上海证券交易所股票上市规则》第 9.5.7 条、 第 9.5.8 条，如公司后续收到行政处罚决定书，显示公司触及重大违法 类强制退市情形，公司将申请停牌，并及时披露有关 ...

Group 1 - The Hong Kong stock market has shown positive performance with notable gains in technology-related companies such as Alibaba, Kuaishou, and SMIC, leading to increased expectations for the A-share market post-holiday [1] - 20 companies have announced share reduction plans, with 9 of them being new reduction plans, including Zhangjiang Hi-Tech, Zhejiang Wenlian, RunDa Medical, and Suotong Development [2] - Zhangjiang Hi-Tech plans to reduce its shares by up to 15,486,895 shares, not exceeding 1% of the total shares, within three months after the announcement [2] Group 2 - Lin'an Xinjing intends to reduce up to 23,746,800 shares, which is 1.60% of the total share capital, with specific limits for different trading methods [4] - RunDa Medical's shareholders, Zhu Wenyi and Liu Hui, plan to reduce their holdings by up to 10,540,000 shares and 7,460,000 shares respectively, representing 1.75% and 1.24% of the total shares [10] - Three companies have issued delisting risk warnings, including ST Dongshi, ST Suwu, and ST Zhengping, indicating potential risks of stock delisting due to low share prices [12] Group 3 - Eight companies have reported abnormal stock trading fluctuations, including Shida Shenghua, Pinming Technology, and Fengshan Group, which have issued announcements regarding these trading anomalies [12]

Wind数据显示，截至9月30日，今年以来上证指数、深证成指、创业板指分别累计上涨15.84%、29.88%、 51.20%。 市场持续走强，低价股数量也随之减少。截至9月30日，最新收盘价（前复权）在2元以下的低价股数量仅剩31 只。 2元以下低价股数量为31只 Wind数据显示，截至9月30日，收盘价（前复权）低于2元的低价股数量为31只。其中股价最低的是*ST高鸿，最 新收盘价为0.38元。 31只低价股中，除紫天退为创业板股票外，其他均为主板股票。按照申万一级行业划分，房地产行业低价股数量 最多，有7只，建筑装饰行业有4只，钢铁行业有3只，医药生物、基础化工、交通运输行业均为2只。 从市值规模看，在31只低价股中，市值低于100亿元的股票有19只，占比超六成；业绩表现方面，有21只低价股 2025年上半年归母净利润为亏损状态，整体业绩表现不佳；从股价表现来看，有22只低价股今年以来股价下跌， 占比超七成。 Wind数据显示，截至9月30日，今年以来，剔除上市新股，A股共有4356只股票涨幅为正，占比超八成。其中， 1361只股票涨幅在50%以上，446只股票涨超100%。 在446只涨幅超100%的股 ...

Core Viewpoint - The introduction of "Miracle Youth 3.0 - Plastic Beauty" by the domestic medical beauty service platform New Oxygen, priced at 2999 yuan, is considered the lowest price in history, breaking the previous market average of over 10,000 yuan, indicating a significant shift in the market dynamics of youth-enhancing injections [1][2]. Market Competition Landscape - The market for youth-enhancing injections, categorized as "medical beauty regenerative injectables," is experiencing intense competition with nine products currently approved in China, consisting of three imported and six domestic brands [3]. - The global market for medical beauty regenerative injectables is projected to reach approximately 11.52 billion yuan by 2027, with a compound annual growth rate (CAGR) of about 31.2% from 2025 to 2027 [2]. Pricing Strategies and Market Dynamics - The current market is characterized by a "mixed battle" phase, with various brands adopting different pricing strategies, including low-dose products to capture market share [6][8]. - The price of existing products typically starts at over 10,000 yuan, with some products like Jiangsu Wuzhong's Aisufei priced at 18,800 yuan before discounts [3]. Future Market Trends - The entry of New Oxygen and the increase in the number of certified manufacturers and qualified doctors are expected to lead to a price reduction in the youth-enhancing injection market, marking a transition towards market maturity [7]. - The Chinese market is anticipated to become a price lowland compared to neighboring countries, where prices are significantly lower [7]. Sales Performance and Market Size - Despite the competitive landscape, companies like Changchun Shengboma and Aimeike have reported substantial sales figures, with Aimeike's revenue from gel injection products reaching 6.38 billion yuan in 2022, and projected to grow to 1.2 billion yuan in 2024 [10]. - The overall market size for youth-enhancing injections is estimated to be in the millions of units, with a rapid increase in market participants from one or two to potentially twenty in the future [11]. Selection Criteria for Products - The selection of products in the market is increasingly based on consumer reputation, price-performance ratio, and the manufacturer's overall strength, as the number of approved products continues to rise [12]. - Brands must focus on building a strong consumer base and professional barriers to survive in the competitive market, emphasizing the importance of doctor expertise in the application of youth-enhancing injections [13]. Emerging Products and Competition - Several new products are in the pipeline for approval, including those from Hangzhou Gai Biological and Huadong Pharmaceutical, which will further intensify competition in the market [14].